Internal standard Product for ADC New Drug Development

Antibody-drug conjugates (ADCs) are targeted drugs composed of antibodies, linkers and cytotoxic molecules. Unlike chemotherapy, ADCs target and kill tumor cells without harming healthy cells, by integrating the antigen specificity of monoclonal antibodies (mAbs) with antibody fragments. The ADC cytotoxin (also known as the payload) is the most important component, as it determines the potency of the ADCs to kill cancer cells. It is the "bullet" responsible for destroying cancer cells[1].

 

Figure 1 ADC drug

Isotope-labeled cytotoxin (such as MMAE-d8, Exatecan-d5 mesylate) have become the gold standard for quantitative detection due to the no matrix effects and high sensitivity in LCMS. This can provide important data support for their pharmacokinetics, biodistribution and facilitate the development of ADC new drugs[2].

References:
  • [1] Nat Rev Drug Discov. 2021 Aug;20(8):583-584.
  • [2] J Labelled Comp Radiopharm. 2014 May 15;57(5):350-7.